Targeting HER3 in EGFR TKI-resistant EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)
Whitepaper
Clinical
Recent technological advancements like antibody-drug conjugates (ADCs) and bispecific antibodies (bsAbs) have improved HER3’s targetability and pharmacological potential.
About the author
Domenique Catalano
Oncology Trialtrove Analyst | Citeline
Domenique Catalano is an Oncology Trialtrove Analyst involved in various data enhancements and projects supporting the Ask the Analyst service. She engages in trial landscape analyses and expert subject matter queries in oncology. With extensive primary and secondary research experience in the clinical trial and pharmaceutical industry, Domenique joined Trialtrove in 2023. A graduate of West Chester University in Pennsylvania, Domenique completed a dual major with a BS in both chemistry (pharmaceutical product development) and biology (cell & molecular concentration) and attained her MBA in 2023.
